QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 neuraxis-q3-eps-024-misses-017-estimate-sales-811414k-miss-1000m-estimate

Neuraxis (AMEX:NRXS) reported quarterly losses of $(0.24) per share which missed the analyst consensus estimate of $(0.17) by 4...

 neuraxis-earnings-preview
Neuraxis Earnings Preview
11/10/2025 16:03:42

 neuraxis-receives-fda-clearance-for-its-percutaneous-electrical-nerve-field-stimulation-technology-to-treat-functional-abdominal-pain-and-nausea-associated-with-functional-dyspepsia-in-patients-aged-8-and-older

NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE:NRXS), a medical technology company commercializing neuromo...

 neuraxis-q2-eps-022-beats-023-estimate-sales-894086k-miss-967250m-estimate

Neuraxis (AMEX:NRXS) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.23) by 4.3...

 earnings-outlook-for-neuraxis
Earnings Outlook For Neuraxis
08/11/2025 18:03:25

 craig-hallum-initiates-coverage-on-neuraxis-with-buy-rating-announces-price-target-of-7

Craig-Hallum analyst Chase Knickerbocker initiates coverage on Neuraxis (AMEX:NRXS) with a Buy rating and announces Price Ta...

 neuraxis-says-proprietary-penfs-technology-officially-incorporated-into-newly-released-clinical-practice-guidelines-issued-by-pediatric-academic-society-for-treatment-of-fap-in-ibs

Practice guidelines published in the Journal of Pediatric Gastroenterology & Nutrition (JPGN) name Percutaneous Electrical ...

 neuraxis-enters-into-definitive-agreements-for-purchase-and-sale-of-15m-shares-at-325shr-in-registered-direct-offering

NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE:NRXS), a medical technology company commercializing neuromo...

 neuraxis-receives-fda-510k-clearance-for-ib-stim-for-treatment-of-pediatric-fap-associated-with-functional-dyspepsia-and-fd-related-nausea-symptoms

•   Significantly expands IB-Stim's total addressable market•   Clearance covers patients aged 8–21•   Seamless go-to-marke...

 neuraxis-q4-eps-023-up-from-085-yoy-sales-76116k-up-from-53146k-yoy

Neuraxis (AMEX:NRXS) reported quarterly losses of $(0.23) per share. This is a 72.94 percent increase over losses of $(0.85) pe...

Core News & Articles

NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE:NRXS), a medical technology company commercializing neuromo...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION